ALEC

Alector, Inc.

$2.21

+0.00 (+0.00%)

Mkt Cap 245.37M

Volume 319,469

52W Range 1.09-3.4

Sector Healthcare

Beta 0.65

EPS (TTM) -1.19

P/E Ratio -1.12

Revenue (TTM) 18.42M

Rev Growth (5Y) -0.1%

EPS Growth (5Y) N/A

AlphaQuality · Grade · Gated

Stable Earnings Power

17.0 / 100 pillar composite (overridden)

Company Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Track Record

Showing latest 4 periods • Swipe for more

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	21.05M	100.56M	97.06M	133.62M	207.09M	21.10M	21.22M	27.68M	3.73M	416,000
Net Income	(142.93M)	(119.05M)	(130.39M)	(133.31M)	(36.33M)	(190.23M)	(105.39M)	(52.25M)	(32.48M)	(15.11M)
EPS	-1.39	-1.23	-1.56	-1.62	-0.45	-2.45	-1.62	-0.76	-0.63	-1.78
Free Cash Flow	(184.07M)	(231.16M)	(186.54M)	(24.45M)	295.30M	(171.77M)	(114.57M)	125.58M	(18.57M)	(15.24M)
FCF / Share	-1.79	-2.39	-2.23	-0.30	3.67	-2.21	-1.86	1.84	-0.36	-1.79
Operating CF	(184.03M)	(229.91M)	(184.16M)	(20.33M)	298.55M	(166.73M)	(99.31M)	127.46M	(17.77M)	(12.99M)
Total Assets	293.24M	468.30M	621.83M	787.65M	814.66M	488.25M	421.91M	308.36M	236.06M	54.11M
Total Debt	36.23M	42.52M	38.92M	43.33M	47.60M	51.26M	48.04M	0	0	0
Cash & Equiv	65.80M	33.02M	74.56M	154.32M	329.15M	49.97M	89.64M	65.47M	32.45M	50.84M
Book Value	30.65M	126.80M	134.16M	214.44M	300.72M	267.53M	194.74M	(97.40M)	(52.03M)	(24.91M)
Return on Equity	-4.66	-0.94	-0.97	-0.62	-0.12	-0.71	-0.54	N/A	N/A	N/A

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Revenue	1.05M	6.24M	3.26M	7.87M	3.67M	54.24M	15.34M	15.08M	15.89M	15.19M	9.11M	56.21M
Net Income	(22.93M)	(37.27M)	(34.67M)	(30.52M)	(40.47M)	(2.07M)	(42.22M)	(38.68M)	(36.08M)	(41.43M)	(44.48M)	1.38M
EPS	-0.21	-0.34	-0.34	-0.30	-0.41	-0.02	-0.44	-0.40	-0.38	-0.49	-0.53	0.02
Free Cash Flow	(49.93M)	(41.69M)	(32.52M)	(49.06M)	(60.80M)	(55.20M)	(50.95M)	(63.13M)	(61.88M)	(46.30M)	(46.45M)	(44.22M)
FCF / Share	-0.45	-0.40	-0.32	-0.49	-0.61	-0.56	-0.53	-0.65	-0.66	-0.55	-0.55	-0.53
Operating CF	(49.81M)	(41.69M)	(32.51M)	(49.05M)	(60.78M)	(55.03M)	(50.73M)	(62.80M)	(61.35M)	(46.07M)	(46.54M)	(43.00M)
Total Assets	239.92M	293.24M	335.29M	356.42M	408.30M	468.30M	516.02M	570.73M	635.49M	621.83M	672.39M	708.74M
Total Debt	34.55M	36.23M	37.88M	39.48M	41.05M	42.52M	34.64M	36.11M	37.56M	38.92M	40.23M	40.94M
Cash & Equiv	76.96M	65.80M	76.50M	44.77M	37.97M	33.02M	37.16M	47.55M	72.55M	74.56M	101.96M	131.54M
Book Value	10.38M	30.65M	57.71M	71.17M	94.61M	126.80M	118.93M	150.57M	178.91M	134.16M	162.56M	196.31M
Return on Equity	-2.21	-1.22	-0.60	-0.43	-0.43	-0.02	-0.35	-0.26	-0.20	-0.31	-0.27	0.01